Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.63 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679816 | 0.82 | SCN9A (0.52) | MRGPRX4SCN9A | |
| SCHEMBL366522 | 0.82 | MRGPRX4 (0.56) | MRGPRX4SCN9ANPC1ALDH1A1RAB9A | |
| SCHEMBL364527 | 0.80 | SCN9A (0.63) | MRGPRX4SCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL371154 | 0.79 | MRGPRX4 (0.62) | MRGPRX4SCN9ASMN1; SMN2 | |
| SCHEMBL22481025 | 0.78 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL680478 | 0.76 | SCN9A (0.55) | SCN9A | |
| SCHEMBL364759 | 0.76 | MRGPRX4 (0.64) | MRGPRX4SCN9ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL367120 | 0.76 | HDAC8 (0.55) | MRGPRX4SCN9A | |
| SCHEMBL22480884 | 0.75 | MRGPRX4 (1.00) | MRGPRX4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22469778 | 0.75 | MRGPRX4 (0.76) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | MRGPRX4 458/4885SCN9A 16/4885NPC1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.